Compare BCG & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCG | TVRD |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | 150 | 12 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.6M | 34.6M |
| IPO Year | N/A | N/A |
| Metric | BCG | TVRD |
|---|---|---|
| Price | $1.69 | $3.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | ★ 80.2K | 34.4K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $56.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.36 | $2.75 |
| 52 Week High | $3.44 | $43.65 |
| Indicator | BCG | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 35.88 | 55.73 |
| Support Level | $1.46 | $3.81 |
| Resistance Level | $1.90 | $4.32 |
| Average True Range (ATR) | 0.19 | 0.28 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 5.62 | 60.60 |
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.